Treatment targeted to cell surface epitopes

Clinical and Experimental Dermatology

Volumn 27, Issue 7, 2002, Pages 591-596

  Mrowietz, U ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; B7 ANTIGEN; BASILIXIMAB; CD2 ANTIGEN; CD4 ANTIGEN; CD86 ANTIGEN; CYCLOSPORIN; DACLIZUMAB; DERMATOLOGICAL AGENT; EPITOPE; ETRETIN; IMMUNOGLOBULIN G4; INTERLEUKIN 2 RECEPTOR; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MONOCLONAL ANTIBODY; PREDNISOLONE; RECEPTOR; SIPLIZUMAB;

CELL SURFACE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; REVIEW; SKIN DISEASE; TREATMENT OUTCOME;

ANIMALS; ANTIGENS, CD2; ANTIGENS, CD80; BIOPSY; CD4-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; PSORIASIS; RATS;

EID: 0036458706     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2230.2002.01171.x     Document Type: Review

References (38)

1. Mrowietz U. Advances in systemic therapy for psoriasis. Clin Exp Dermatol 2001; 26: 362-7.
2. Mease PJ, Goffe BS, Metz J et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. Lancet 2000; 356: 385-90.
3. Chaudhari U, Romano P, Mulcahy LD et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial. Lancet 2001; 357: 1842-7.
4. Prinz J, Braun Falco O, Meurer M et al. Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis. Lancet 1991; 338: 320-1.
5. Nicholas JF, Chamchick N, Thivolet J et al. CD4 antibody treatment of severe psoriasis. Lancet 1991; 338: 321.
6. Parnes JR. Molecular biology and function of CD4 and CD8. Adv Immunol 1989; 44: 265-311.
7. Christophers E, Mrowietz U. The inflammatory infiltrate in psoriasis. Clinics Dermatol 1995; 13: 131-5.
8. Morel P, Revillard JP, Nicolas JF et al. Anti-CD4 monoclonal antibody therapy in severe psoriasis. J Autoimmun 1992; 5: 465-77.
9. Rizova H, Nicolas JF, Morel P et al. The effect of anti-CD4 monoclonal antibody treatment on immunopathological changes in psoriatic skin. J Dermatol Sci 1994; 7: 1-13.
10. Morel P, Nicolas JF, Wijdenes J et al. Down-regulation of lymphocyte CD4 antigen expression by administration of anti-CD4 monoclonal antibody. Clin Immunol Immunopathol 1992; 64: 248-53.
11. Isaacs JD, Burrows N, Wing M et al. Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease. Clin Exp Immunol 1997; 110: 158-66.
12. Gottlieb AB, Lebwohl M, Shirin S et al. Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: Results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol 2000; 43: 595-604.
13. Beyers AD, Barclay AN. Law DA et al. Activation of T lymphocytes via monoclonal antibodies against rat cell surface antigens with particular reference to CD2 antigen. Immunol Rev 1989; 111: 59-77.
14. Hoffmann JC, Herklotz C, Zeidler H et al. Anti-CD2 (OX34) MoAb treatment of adjuvant arthritic rats: Attenuation of established arthritis, selective depletion of CD4+ T cells, and CD2 down-modulation. Clin Exp Immunol 1997; 110: 63-71.
15. Sido B, Dengler TJ, Otto G et al. Differential immunosuppressive activity of monoclonal CD2 antibodies on allograft rejection versus specific antibody production. Eur J Immunol 1998; 28: 1347-57.
16. Papp K, Langley R, Matheson R, Dingivan C. Safety, tolerance, and biological activity of MEDI-507 (siplizumab) for the treatment of moderate to severe psoriasis. 60th Annual Meeting of the American Academy of Dermatology. 2002.
17. Branco L, Barren P, Mao SY et al. Selective deletion of antigen-specific, activated T cells by a humanized MAB to CD2 (MEDI-507) is mediated by NK cells. Transplantation 1999; 68: 1588-96.
18. Danielian S, Fagard R, Alcover A et al. The tyrosine kinase activity of p56lck is increased in human T cells activated via CD2. Eur J Immunol 1991; 21: 1967-70.
19. Miller GT, Hochman PS, Meier W et al. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med 1993; 178: 211-22.
20. Kaplon RJ, Hochman PS, Michler RE et al. Short course single agent therapy with an LFA-3-IgG1 fusion protein prolongs primate cardiac allograft survival. Transplantation 1996; 61: 356-63.
21. da Silva AJ, Brickelmaier M, Majeau GR et al. Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2+ cells. J Immunol 2002; 168: 4462-71.
22. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345: 248-55.
23. Waldmann TA. The multi-subunit interleukin-2 receptor. Annu Rev Biochem 1989; 58: 875-911.
24. Carswell CI, Plosker GL, Wagstaff AJ. Daclizumab: A review of its use in the management of organ transplantation. Biodrugs 2001; 15: 745-73.
25. Pascual J, Marcen R, Ortuno J. Anti-interleukin-2 receptor antibodies: Basiliximab and daclizumab. Nephrol Dial Transplant 2001; 16: 1756-60.
26. Owen CM, Harrison PV. Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody. Clin Exp Dermatol 2000; 25: 195-7.
27. Mrowietz U, Zhu K, Christophers E. Treatment of severe psoriasis with anti-CD25 monoclonal antibodies. Arch Dermatol 2000; 136: 675-6.
28. Salim A, Emerson RM, Dalziel KL. Successful treatment of severe generalized pustular psoriasis with basiliximab (interleukin-2 receptor blocker). Br J Dermatol 2000; 143: 1121-2.
29. Wohlrab J, Fischer M, Taube KM et al. Treatment of recalcitrant psoriasis with daclizumab. Br J Dermatol 2001; 144: 209-10.
30. Krueger JG, Walters IB, Miyazawa M et al. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol 2000; 43: 448-58.
31. Kägi MK, Heyer G. Efficacy of basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in a patient with severe chronic atopic dermatitis. Br J Dermatol 2001; 145: 350-1.
32. Willenbacher W, Basara N, Blau IW et al. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br J Haematol 2001; 112: 820-3.
33. Slavik JM, Hutchcroft JE, Bierer BE. CD28/CTLA-4 and CD80/CD86 families: Signaling and function. Immunol Res 1999; 19: 1-24.
34. Davenport CM, McAdams HA, Kou J et al. Inhibition of pro-inflammatory cytokine generation by CTLA4-Ig in the skin and colon of mice adoptively transplanted with CD45RBhi CD4+ T cells correlates with suppression of psoriasis and colitis. Int Immunopharmacol 2002; 2: 653-72.
35. Abrams JR, Lebwohl MG, Guzzo CA et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999; 103: 1243-52.
36. Abrams JR, Kelley SL, Hayes E et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000; 192: 681-94.
37. Schopf RE. IDEC-114 (IDEC). Curr Opin Invest Drugs 2001; 2: 635-8.
38. Gottlieb A, Abdulghani A, Totoritis M, et al. Results of a single-dose, dose-escalating trial of an anti-B7.1 monoclonal antibody (IDEC-114) in patients with psoriasis. J Invest Dermatol 2000; 114: 840.